News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
682,864 Results
Type
Article (38954)
Company Profile (276)
Press Release (643634)
Section
Business (203814)
Career Advice (1985)
Deals (35356)
Drug Delivery (83)
Drug Development (80764)
Employer Resources (168)
FDA (16083)
Job Trends (14796)
News (344449)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1209)
Approvals (16002)
Artificial intelligence (112)
Bankruptcy (352)
Best Places to Work (11456)
Biotechnology (196)
Breast cancer (100)
Cancer (875)
Career advice (1657)
Cell therapy (191)
Clinical research (63867)
Collaboration (315)
Compensation (156)
COVID-19 (2520)
Cystic fibrosis (78)
Data (821)
Diabetes (126)
Diagnostics (6088)
Drug pricing (75)
Earnings (84051)
Employer resources (145)
Events (108729)
Executive appointments (238)
FDA (16506)
Funding (280)
Gene therapy (146)
GLP-1 (552)
Government (4316)
Healthcare (18647)
Infectious disease (2592)
Inflammatory bowel disease (101)
Interviews (308)
IPO (16263)
Job creations (3622)
Job search strategy (1415)
Layoffs (407)
Legal (7847)
Lung cancer (153)
Manufacturing (145)
Medical device (13136)
Medtech (13141)
Mergers & acquisitions (19097)
Metabolic disorders (345)
Neuroscience (1444)
NextGen Class of 2024 (6493)
Non-profit (4462)
Northern California (1161)
Obesity (207)
Opinion (175)
Patents (93)
People (56096)
Phase I (19808)
Phase II (28116)
Phase III (21001)
Pipeline (199)
Postmarket research (2553)
Preclinical (8422)
Radiopharmaceuticals (234)
Rare diseases (178)
Real estate (5888)
Regulatory (21421)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1050)
Startups (3560)
United States (11324)
Vaccines (532)
Weight loss (154)
Date
Today (178)
Last 7 days (823)
Last 30 days (2880)
Last 365 days (35990)
2024 (29970)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (186)
Asia (36989)
Australia (6033)
California (2637)
Canada (1152)
China (205)
Colorado (113)
Connecticut (116)
Europe (79186)
Florida (378)
Georgia (96)
Illinois (306)
Indiana (175)
Kansas (95)
Maryland (505)
Massachusetts (2140)
Michigan (142)
Minnesota (246)
New Jersey (801)
New York (813)
North Carolina (654)
Northern California (1161)
Ohio (123)
Pennsylvania (734)
South America (1091)
Southern California (1050)
Texas (366)
Utah (77)
Washington State (313)
682,864 Results for "ribometrix inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
September 16, 2024
·
4 min read
Bio NC
Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024
Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, shared the full data from two posters highlighting advancements across two distinct modalities presented at the 2024 American Association for Cancer Research Annual Meeting, held April 5-10 in San Diego, CA.
April 7, 2024
·
6 min read
Bio NC
Ribometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting
Ribometrix today announced it will present two posters with preclinical data highlighting advancements across two distinct modalities at the 2024 American Association for Cancer Research (AACR) Annual Meeting.
March 11, 2024
·
3 min read
Bio NC
Ribometrix Demonstrates Rapid Progress for eIF4E Program at San Antonio Breast Cancer Symposium
Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today presented preclinical data supporting the potential of its eIF4E inhibitors in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium (SABCS), held December 5-9, 2023, in San Antonio, TX.
December 8, 2023
·
4 min read
Bio NC
Ribometrix to Present Additional Preclinical Data for eIF4E Program at the San Antonio Breast Cancer Symposium
Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today announced it will present preclinical data showing anti-tumor benefit of eIF4E inhibition in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium, held December 5-9, 2023, in San Antonio, TX.
November 29, 2023
·
2 min read
Bio NC
Ribometrix Announces Lead Program Target and Presentation of Preclinical Data at the International Congress of the Society for Melanoma Research
Ribometrix today disclosed its lead wholly-owned development program targeting the protein eIF4E, and announced it will present initial preclinical data demonstrating the anti-tumor benefit of eIF4E inhibition at the 20th International Congress of the Society for Melanoma Research (SMR), held November 6-9, 2023, in Philadelphia, PA.
November 6, 2023
·
4 min read
Business
Ribometrix Promotes Dr. Manjunath Ramarao to Chief Scientific Officer
Ribometrix announced today the promotion of Manjunath (Manju) Ramarao, Ph.D., to chief scientific officer.
March 21, 2022
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.
Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).
June 20, 2024
·
4 min read
1 of 68,287
Next